Islam Badr Ezzeldin Mohamed

Dr. Islam Badr Ezzeldin Mohamed

Baylor College of Medicine, Houston, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2022 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
ASAhmed El Sabagh
Ahmed El Sabagh
IMIslam Badr Ezzeldin Mohamed
Islam Badr Ezzeldin Mohamed
FAFuad Zain Aloor
Fuad Zain Aloor
AAAhmed Abdelwahab
Ahmed Abdelwahab
MHManal M. Hassan
Manal M. Hassan
PJPrasun Jalal
Prasun Jalal

25 September 2014 in Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
AAAhmed Kamel Abdel-Aal
Ahmed Kamel Abdel-Aal
IMIslam Badr Ezzeldin Mohamed
Islam Badr Ezzeldin Mohamed
MHMaysoon Farouk Hamed
Maysoon Farouk Hamed
RIRafik Mohamed Ibrahim
Rafik Mohamed Ibrahim
MBMax Berry
Max Berry
SSSouheil Saddekni
Souheil Saddekni
We report a case of extensive acute portal vein thrombosis (PVT) presenting with severe diffuse abdominal pain and impending small bowel infarction. The patient was successfully treated with ultrasound-accelerated catheter-directed thrombolysis (EKOS endowave system; Covidien, Mansfield, Massachusetts), which resulted in prompt recanalization of his portal vein (PV) and its tributaries. The patient eventually had ischemic stricture that necessitated bowel resection. However, we believe that our technique was successful in rapidly restoring the patency of the PV and its tributaries, and therefore, avoiding a life-threatening complication of more extensive bowel infarction. To our knowledge, the use of ultrasound-accelerated thrombolysis in treatment of PVT has not been previously described in the literature.

21 January 2026 in Hepatology Communications
Verified
Journal Article
Open access
MIMohamad Ali Ibrahim
Mohamad Ali Ibrahim
NRNagham Ramadan
Nagham Ramadan
IMIslam Badr Ezzeldin Mohamed
Islam Badr Ezzeldin Mohamed
CACaroline Ankoma-Sey
Caroline Ankoma-Sey
SFSherry Fares
Sherry Fares
PJPrasun Jalal
Prasun Jalal
Background: In patients with steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease (MetALD) is a recently defined entity combining metabolic syndrome and moderate-to-high alcohol consumption. Its prognosis and outcomes compared with alcohol-associated liver disease (ALD) remain underexplored. The aim of the study was to assess liver recompensation (LR) between the 2 groups in patients with decompensated liver disease referred for liver transplant (LT) evaluation. Methods: We conducted a retrospective cohort study of 194 patients with decompensated liver disease, diagnosed as MetALD or ALD, and referred for LT evaluation between October 2021 and August 2023 at a single U.S. transplant center, and compared the outcomes between the 2 groups. The diagnoses of MetALD and ALD were based on the Delphi consensus definitions. Results: Of the 194 patients, 135 (70%) had ALD and 59 (30%) had MetALD. Baseline characteristics showed significantly higher BMI (31 vs. 28 kg/m 2 , p =0.001), chronic kidney disease (32% vs. 17%, p =0.025), and lower Karnofsky scores (51 vs. 62, p =0.014) in the MetALD group. While no statistical difference was found in listing and LT rates between groups, LR occurred significantly less in MetALD compared with ALD (3% vs. 18%, p =0.006). On multivariable analysis, MetALD independently predicted lower LR (HR 0.21, 95% CI: 0.05–0.91). Hypertension (HR 0.38, 95% CI: 0.16–0.89) and increasing BMI (HR 0.91, 95% CI: 0.84–0.99) were also significantly associated with lower LR. While overall mortality was higher in the MetALD group (42% vs. 26%, p =0.029), MetALD was not an independent mortality predictor after adjustment. Conclusions: Compared with ALD, MetALD is associated with significantly lower LR in patients with decompensated liver diseases referred for LT evaluation.

16 June 2023 in Cancer Medicine
Verified
Journal Article
Open access
IMIslam Badr Ezzeldin Mohamed
Islam Badr Ezzeldin Mohamed
MIMohamed Saleh Ismail
Mohamed Saleh Ismail
ASAhmed El Sabagh
Ahmed El Sabagh
AAAhmed M. Afifi Abdelwahab
Ahmed M. Afifi Abdelwahab
EPEfstathia Polychronopoulou
Efstathia Polychronopoulou
PJPrasun Jalal
Prasun Jalal
Background and Aims: Contrast‐enhanced cross‐sectional imaging is the cornerstone in the diagnosis, staging, and management of HCC, including eligibility for liver transplantation (LT). Radiological‐histopathological discordance may lead to improper staging and may impact patient outcomes. We aimed to assess the radiological‐histopathological discordance at the time of LT in HCC patients and its impact on the post‐LT outcomes.Methods: We analyzed further the effect of 6‐month waiting policy on the discordance. Using United Network for Organ Sharing—Organ Procurement and Transplantation Network (UNOS‐OPTN) database, we examined the discordance between pre‐LT imaging and explant histopathology for all adult HCC patients who received liver transplants from deceased donors between April 2012 and December 2017. Kaplan–Meier methods and Cox regression analyses were used to evaluate the impact of discordance on 3‐year HCC recurrence and mortality.Results: Of 6842 patients included in the study, 66.7% were within Milan criteria on both imaging and explant histopathology, and 33.3% were within the Milan based on imaging but extended beyond Milan on explant histopathology. Male gender, increasing numbers of tumors, bilobar distribution, larger tumor size, and increasing AFP are associated with increased discordance. Post‐LT HCC recurrence and death were significantly higher in patients who were discordant, with histopathology beyond Milan (adj HR 1.86, 95% CI 1.32–2.63 for mortality and 1.32, 95% CI 1.03–1.70 for recurrence). Graft allocation policy with 6‐month waiting time led to increased discordance (OR 1.19, CI 1.01–1.41), although it did not impact post‐LT outcome.Conclusion: Current practice for staging of HCC based on radiological imaging features alone results in underestimation of HCC burden in one out of three patients with HCC. This discordance is associated with a higher risk of post‐LT HCC recurrence and mortality. These patients will need enhanced surveillance to optimize patient selection and aggressive LRT to reduce post‐LT recurrence and increase survival.

2 November 2021 in Transplantology
Verified
Journal Article
Open access
PDF file
IMIslam Badr Ezzeldin Mohamed
Islam Badr Ezzeldin Mohamed
FAFuad Zain Aloor
Fuad Zain Aloor
PJPrasun Jalal
Prasun Jalal
Since the first liver transplantation operation (LT) in 1967 by Thomas Starzl, efforts to increase survival and prevent rejection have taken place. The development of calcineurin inhibitors (CNIs) in the 1980s led to a surge in survival post-transplantation, and since then, strategies to prevent graft loss and preserve long-term graft function have been prioritized. Allograft rejection is mediated by the host immune response to donor antigens. Prevention of rejection can be achieved through either immunosuppression or induction of tolerance. This leads to a clinical dilemma, as the choice of an immunosuppressive agent is not an easy task, with considerable patient and graft-related morbidities. On the other hand, the induction of graft tolerance remains a challenge. Despite the fact that the liver exhibits less rejection than any other transplanted organs, spontaneous graft tolerance is rare. Most immunosuppressive medications have been incriminated in renal, cardiovascular, and neurological complications, relapse of viral hepatitis, and recurrence of HCC and other cancers. Efforts to minimize immunosuppression are directed toward decreasing medication side effects, increasing cost effectiveness, and decreasing economic burden without increasing the risk of rejection. In this article, we will discuss recent advances in strategies for improving immunosuppression following liver transplantation.

28 December 2015 in Journal of Radiology Case Reports
Verified
Journal Article
Open access
AAAhmed Kamel Abdel Aal
Ahmed Kamel Abdel Aal
IMIslam Badr Ezzeldin Mohamed
Islam Badr Ezzeldin Mohamed
AMAmr Soliman Moustafa
Amr Soliman Moustafa
NENathan Ertel
Nathan Ertel
RORachel Oser
Rachel Oser
We report a case of an indwelling inferior vena cava filter that penetrated the IVC wall after Whipple's pancreatico-duodenectomy procedure performed in a patient with ampullary carcinoma, resulting in right ureteral injury and obstruction with subsequent hydroureter and hydronephrosis. This was incidentally discovered on a computed tomography scan performed as routine follow up to evaluate the results of the surgery. We retrieved the inferior vena cava filter and placed a nephrostomy catheter to relieve the ureteral obstruction. Our case highlights the importance of careful inferior vena cava manipulation during abdominal surgery in the presence of an inferior vena cava filter, and the option of temporary removal of the filter to be placed again after surgery in order to avoid this complication, unless protection is required against clot migration during the surgical procedure.